Abstract
This study aimed to evaluate the association between the delta neutrophil index (DNI), which reflects immature granulocytes, and the severity of ST-elevation myocardial infarction (STEMI), as well as to determine the significance of the DNI as a prognostic marker for early mortality and other clinical outcomes in patients with STEMI who underwent reperfusion. This retrospective, observational cohort study was conducted using patients prospectively integrated in a critical pathway program for STEMI. We included 842 patients diagnosed with STEMI who underwent primary percutaneous coronary intervention (pPCI). Higher DNI values at time-I (within 2 h of pPCI; hazard ratio [HR], 1.075; 95% confidence interval [CI]: 1.046–1.108; p < 0.001) and time-24 (24 h after admission; HR, 1.066; 95% CI: 1.045–1.086; p < 0.001) were significant independent risk factors for 30-day mortality. Specifically, DNI values >2.5% at time-I (HR, 13.643; 95% CI: 8.13–22.897; p < 0.001) and > 2.9% at time-24 (HR, 12.752; 95% CI: 7.308–22.252; p < 0.001) associated with increased risks of 30-day mortality. In conclusion, an increased DNI value, which reflects the proportion of circulating immature granulocytes in the blood, was found to be an independent predictor of 30-day mortality and poor clinical outcomes in patients with acute STEMI post-pPCI.
Highlights
Acute myocardial infarction (AMI) remains a major cause of mortality and morbidity worldwide, causing more than 150,000 deaths in the USA each year[1,2]
An intense inflammatory response is activated in the early stage of cardiac ischaemic injury; this contributes significantly to ventricular remodelling after AMI3
Tamhane et al demonstrated that neutrophilia >65% in patients with ST-elevation myocardial infarction (STEMI) reflected worse angiographic outcomes, large infarct size, and increased risk of short-term mortality[16]
Summary
Acute myocardial infarction (AMI) remains a major cause of mortality and morbidity worldwide, causing more than 150,000 deaths in the USA each year[1,2]. Despite recent improvements in critical care medicine, patients with ST-segment elevation myocardial infarction (STEMI) on the presenting electrocardiogram (ECG) remain at increased risk of mortality and serious morbidity if they survive the initial ischaemic event[3]. Many studies have attempted to develop cardiac-specific markers or risk scoring systems to identify patients at increased risk and to provide prognostic information[5]. The roles of inflammatory markers for severity assessment in the early stage of STEMI have been attracting interest. Despite experimental and clinical evidence of the associations between inflammation and adverse outcomes, no specific inflammatory biomarkers are currently routinely used in the management of patients with STEMI3,9. We evaluated the significance of the DNI as a prognostic marker of early mortality in patients with STEMI who underwent pPCI. To the best of our knowledge, this is the first study to evaluate the association between the DNI and the severity of STEMI in the clinical setting
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.